Ken Griffin Fennec Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$8.82 - $11.12 $58,212 - $73,392	6,600 Added 67.35%	16,400 $182,000
Q4 2023 Feb 14, 2024	SELL	$6.48 - $11.61 $20,088 - $35,991	-3,100 Reduced 24.03%	9,800 $109,000
Q3 2023 Nov 14, 2023	SELL	$7.15 - $8.94 $338,195 - $422,862	-47,300 Reduced 78.57%	12,900 $96,000
Q2 2023 Aug 14, 2023	SELL	$7.27 - $9.82 $242,091 - $327,006	-33,300 Reduced 35.61%	60,200 $531,000
Q1 2023 May 15, 2023	SELL	$7.38 - $10.35 $395,568 - $554,760	-53,600 Reduced 36.44%	93,500 $777,000

Q4 2022 Feb 14, 2023	BUY	$7.91 - $10.22 $855,071 - $1.1 Million	108,100 Added 277.18%	147,100 $1.41 Million
Q3 2022 Nov 14, 2022	BUY	$5.71 - $8.54 $222,690 - $333,059	39,000 New	39,000 $316,000

14.4M

53.2K

83.9K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $159M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.